Myovant Sciences Return on Investment 2017-2022 | MYOV

Current and historical return on investment (ROI) values for Myovant Sciences (MYOV) over the last 10 years.
Myovant Sciences ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.19B $-0.12B 294.49%
2021-12-31 $-0.21B $-0.07B 632.84%
2021-09-30 $-0.23B $-0.02B 5411.76%
2021-06-30 $-0.28B $-0.04B -1862.30%
2021-03-31 $-0.26B $0.01B -648.45%
2020-12-31 $-0.25B $0.04B -616.15%
2020-09-30 $-0.25B $0.05B -542.08%
2020-06-30 $-0.24B $0.06B -408.40%
2020-03-31 $-0.27B $0.01B -314.94%
2019-12-31 $-0.28B $0.07B -255.78%
2019-09-30 $-0.27B $0.11B -210.00%
2019-06-30 $-0.27B $0.17B -203.77%
2019-03-31 $-0.27B $0.10B -227.96%
2018-12-31 $-0.24B $0.14B -214.29%
2018-09-30 $-0.21B $0.12B -205.30%
2018-06-30 $-0.18B $0.10B -241.89%
2018-03-31 $-0.14B $0.08B -293.75%
2017-12-31 $-0.12B $0.11B -421.62%
2017-09-30 $-0.08B inf%
2017-06-30 $-0.06B inf%
2017-03-31 $-0.06B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00